Unicycive Therapeutics stock (US90467V1098): Q1 2026 results and PDUFA update

Unicycive Therapeutics reported Q1 2026 financial results with a net loss of $12.8 million and $57.1 million in cash. FDA PDUFA date for oxylanthanum carbonate NDA set for June 29, 2026.

Unicycive Therapeutics (Nasdaq: UNCY) released its first quarter 2026 financial results on May 12, 2026, reporting a net loss of $12.8 million for the period ended March 31, 2026. The clinical-stage biotech maintains $57.1 million in cash and investments, sufficient to fund operations into 2027. The FDA accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), with a PDUFA target action date of June 29, 2026, according to StockTitan as of May 12, 2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Unicycive Therapeutics, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: Los Altos, California, USA
• Core markets: United States
• Key revenue drivers: Kidney disease therapies
• Home exchange/listing venue: Nasdaq (UNCY)
• Trading currency: USD

Unicycive Therapeutics: core business model

Unicycive Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for kidney diseases. Its lead candidate, oxylanthanum carbonate (OLC), is an investigational oral phosphate binder for hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis, currently under FDA review, as detailed in the company's Q1 2026 press release as of May 12, 2026. The second program, UNI-494, targets acute kidney injury and is in Phase 1 trials.

Founded in 2016 and headquartered in Los Altos, California, Unicycive targets unmet needs in the US kidney disease market, where CKD affects millions, providing relevance for US investors tracking biotech innovations in nephrology.

Main revenue and product drivers for Unicycive Therapeutics

Future revenue hinges on OLC commercialization post-FDA approval. The NDA resubmission in January 2026 addressed prior issues, with the FDA confirming no concerns on preclinical, clinical, or safety data, per the May 12, 2026 announcement. Hyperphosphatemia impacts a significant portion of the 550,000+ US dialysis patients annually.

UNI-494 represents a pipeline diversifier for acute kidney injury, a condition linked to high hospital mortality rates. Cash reserves of $57.1 million as of March 31, 2026, support R&D and pre-commercial activities into 2027 without near-term dilution risks.

Industry trends and competitive position

The kidney disease therapeutics market is expanding due to rising CKD prevalence from diabetes and hypertension in the US. Phosphate binders like OLC compete with established players such as sevelamer and lanthanum carbonate, but Unicycive emphasizes OLC's potential lower pill burden and improved tolerability.

Unicycive's Nasdaq listing and California base position it well for US institutional interest, with analyst price targets averaging $24.75 versus recent trading around $3.71-$11.00 in the 52-week range, according to MarketBeat as of May 12, 2026.

Why Unicycive Therapeutics matters for US investors

Unicycive addresses critical US healthcare needs, with CKD impacting over 37 million Americans. A positive PDUFA outcome could drive value in the biotech sector, where kidney-focused firms have seen approvals translate to multi-fold returns. Its Nasdaq presence facilitates easy access for US retail and institutional portfolios.

Conclusion

Unicycive Therapeutics' Q1 2026 results highlight a solid cash position and advancing regulatory milestone with the June 29 PDUFA for OLC. While pre-revenue with ongoing losses, the pipeline progress in kidney disease therapies underscores potential catalysts ahead. Investors monitor FDA feedback amid biotech sector volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.